J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity.
ILS-920 is a Rapamycin analog characterized by diminished immunosuppressiveeffects but remarkable neuroprotective properties. It exhibits selective binding affinity towards the immunophilin FKBP52 as well as the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 displays a notable 200-fold preference for FKBP52 over FKBP12.
CD73-IN-8, a potent CD73 inhibitor, prevents the catalytic activity of CD73, an enzyme responsible for converting extracellular 5'-phosphate adenosine (5'-AMP) to adenosine. Adenosine, once produced, can induce immunosuppressiveeffects and facilitate tumor proliferation and or metastasis. Therefore, CD73-IN-8 holds promise in the development of therapeutic interventions for tumor-related diseases[1].
Mycophenolic acid sodium is a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), exhibiting an EC50 of 0.24 μM. It has broad antiviral activity against RNA viruses, including influenza. Additionally, mycophenolic acid sodium possesses immunosuppressive properties and exerts antiangiogenic and antitumor effects [1][2].